Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies - Additional Information (Detail)

v3.6.0.2
Commitments and Contingencies - Additional Information (Detail)
 1 Months Ended 4 Months Ended 12 Months Ended
Aug. 01, 2015
ft²
Apr. 24, 2015
USD ($)
Aug. 31, 2016
USD ($)
Feb. 28, 2015
USD ($)
ft²
Dec. 31, 2009
USD ($)
Apr. 24, 2015
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Dec. 31, 2016
CAD
Sep. 30, 2016
USD ($)
May 14, 2015
Feb. 01, 2015
USD ($)
Other Commitments [Line Items]                          
Gross proceeds                 $ 22,372,000        
Expiration of operating lease agreement             2016-09            
Additional office space | ft² 2,245                        
Consolidated rent and facilities expense             $ 600,000 $ 900,000 $ 2,800,000        
Lease termination agreement, additional fee payable       $ 1,300,000                  
Indemnification obligations             0            
Expenses related to indemnification issues             0            
Vancouver, Canada [Member]                          
Other Commitments [Line Items]                          
Aggregate future minimum annual lease payments under the lease             68,000,000            
Ionis Pharmaceuticals Inc. [Member]                          
Other Commitments [Line Items]                          
Litigation settlement, upfront payment     $ 1,400,000                    
Royalty payment percentage     5.00%                    
Sale, license or other transaction payment percentage     50.00%                    
Ionis Pharmaceuticals Inc. [Member] | Maximum [Member]                          
Other Commitments [Line Items]                          
Litigation settlement, success based payment     $ 5,000,000                    
Grosvenor International Limited [Member]                          
Other Commitments [Line Items]                          
Area of office space leased | ft²       11,526                  
Expiration date of option to lease additional area of office space       Aug. 01, 2015                  
Lease expiration date       Apr. 30, 2018                  
Optional lease renewal       3 years                  
Monthly base rent commencement date       May 01, 2015                  
Lessee's share of property tax percentage.       17.00%                  
Construction allowance received for leasehold improvements                         $ 100,000
Deposit amount under lease agreement                         $ 200,000
Grosvenor International Limited [Member] | Maximum [Member]                          
Other Commitments [Line Items]                          
Monthly base rent       $ 20,000                  
Grosvenor International Limited [Member] | Minimum [Member]                          
Other Commitments [Line Items]                          
Monthly base rent       $ 18,000                  
BMR-217TH Place LLC [Member]                          
Other Commitments [Line Items]                          
Lease termination agreement, date of termination       Mar. 01, 2015                  
Letter of credit drawn to pay deferred state sales tax       $ 100,000                  
Letter of credit terminated       200,000                  
Terminated lease       500,000                  
Reversed lease termination liability current                     $ 1,300,000    
BMR-217TH Place LLC [Member] | Termination Fee [Member]                          
Other Commitments [Line Items]                          
Lease termination agreement, fee payable       2,000,000                  
BMR-217TH Place LLC [Member] | Minimum [Member]                          
Other Commitments [Line Items]                          
Amount of funding to raise that would trigger payment of additional termination fee       $ 20,000,000                  
Collaborative Arrangement [Member] | Teva Pharmaceutical Industries Ltd. [Member]                          
Other Commitments [Line Items]                          
Proceeds from advance reimbursement research and development           $ 27,000,000              
Hold-back amount and third-party expenses deducted from advanced reimbursement payment   $ 3,800,000       3,800,000              
Hold-back amount deducted from advanced reimbursement payment   3,000,000       3,000,000              
Third-party expenses deducted from advanced reimbursement payment           $ 800,000              
Maximum cost exposure if third-party agreements discovered after the termination date             100,000            
Collaboration agreement aggregate amount         $ 50,000,000                
Gross proceeds             10,000,000            
Direct and indirect costs incurred             $ 30,000,000            
Collaborative Arrangement [Member] | Ionis Pharmaceuticals Inc. [Member]                          
Other Commitments [Line Items]                          
Collaboration agreement aggregate amount   $ 23,200,000                      
Net proceed from collaboration agreement amount, requested payment percentage                       20.00%  
Hold-back amount, requested payment percentage                       30.00%  
Lawsuit filing date             January 2016            
Range of each product line             10 years            
Collaborative Arrangement [Member] | Ionis Pharmaceuticals Inc. [Member] | Maximum [Member]                          
Other Commitments [Line Items]                          
Milestone payments             $ 7,750,000            
Collaborative Arrangement [Member] | University of British Columbia [Member] | Maximum [Member]                          
Other Commitments [Line Items]                          
Milestone payments | CAD                   CAD 1,600,000